ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Intellia Therapeutics Inc

Intellia Therapeutics Inc (0JBU)

24,34
0,00
( 0,00% )
Aktualisiert: 02:00:00

Intellia Therapeutics Inc (0JBU) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
24,34
( - )
Gebot
24,34
Fragen
24,34
Volumen
843
0,00 Tagesbereich 0,00
24,34 52-Wochen-Bereich 24,34
Marktkapitalisierung
Handelsende
24,34
Handelsbeginn
-
Letzte Trade
3
@
15.82
(O)
Letzter Handelszeitpunkt
14:51:12
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
US$ 6.378.101
Ausgegebene Aktien
139.722.277
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-4,45
Gewinn pro Aktie (EPS)
-3,52
Erlöse (LTM)
66,09M
Nettogewinn (LTM)
-394,6M

Über Intellia Therapeutics Inc

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technolo... Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Mehr anzeigen

Sektor
-
Branche
-
Hauptsitz
Cambridge, United States
Gegründet
2026
Intellia Therapeutics Inc is listed in the sector of the Londoner Börse with ticker 0JBU. The last closing price for Intellia Therapeutics was US$24,34. Over the last year, Intellia Therapeutics shares have traded in a share price range of US$ 24,34 to US$ 24,34.

Intellia Therapeutics currently has 139.722.277 shares in issue. The market capitalisation of Intellia Therapeutics is US$3,40 billion. Intellia Therapeutics has a price to earnings ratio (PE ratio) of -4.45.

0JBU Neueste Nachrichten

Keine Nachrichten vorhanden.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DE
40000000DE
120000000DE
260024.3424.3424.342027624.34DE
520024.3424.3424.342590224.34DE
1560024.3424.3424.341194324.34DE
2600024.3424.3424.34704824.34DE

0JBU - Frequently Asked Questions (FAQ)

What is the current Intellia Therapeutics Inc share price?
The current share price of Intellia Therapeutics Inc is US$ 24,34
How many Intellia Therapeutics Inc shares are in issue?
Intellia Therapeutics Inc has 139.722.277 shares in issue
What is the market cap of Intellia Therapeutics Inc?
The market capitalisation of Intellia Therapeutics Inc is USD 3,4B
What is the 1 year trading range for Intellia Therapeutics Inc share price?
Intellia Therapeutics Inc has traded in the range of US$ 24,34 to US$ 24,34 during the past year
What is the PE ratio of Intellia Therapeutics Inc?
The price to earnings ratio of Intellia Therapeutics Inc is -4,45
What is the cash to sales ratio of Intellia Therapeutics Inc?
The cash to sales ratio of Intellia Therapeutics Inc is 33,13
What is the registered address of Intellia Therapeutics Inc?
The registered address for Intellia Therapeutics Inc is 40 Erie Street, Cambridge, Massachusetts, 02139
What is the Intellia Therapeutics Inc website address?
The website address for Intellia Therapeutics Inc is www.intelliatx.com

0JBU Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen